Identification of FDA-approved drugs that increase mevalonate kinase in hyper IgD syndrome

被引:1
|
作者
Politiek, Frouwkje A. [1 ,2 ]
Turkenburg, Marjolein [1 ]
Koster, Janet [1 ]
Ofman, Rob [1 ]
Waterham, Hans R. [1 ,2 ,3 ,4 ]
机构
[1] Amsterdam Univ Med Ctr, Acad Med Ctr, Dept Lab Med, Lab Genet Metab Dis, Amsterdam, Netherlands
[2] Amsterdam Gastroenterol Endocrinol & Metab, Amsterdam, Netherlands
[3] Amsterdam Reprod & Dev, Amsterdam, Netherlands
[4] Amsterdam Univ Med Ctr, Acad Med Ctr, Lab Genet Metab Dis F0 222, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
关键词
cholesterol biosynthesis; clobetasol propionate; glucocorticoids; mevalonate kinase deficiency; systemic autoinflammatory diseases; HYPERIMMUNOGLOBULINEMIA-D; CHOLESTEROL; DEFICIENCY; MUTATIONS; PHENOTYPE; SERIES; BIOSYNTHESIS; GENOTYPE; SPECTRUM; CELLS;
D O I
10.1002/jimd.12698
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Mevalonate kinase deficiency (MKD) is an autoinflammatory metabolic disorder caused by bi-allelic loss-of-function variants in the MVK gene, resulting in decreased activity of the encoded mevalonate kinase (MK). Clinical presentation ranges from the severe early-lethal mevalonic aciduria to the milder hyper-IgD syndrome (MKD-HIDS), and is in the majority of patients associated with recurrent inflammatory episodes with often unclear cause. Previous studies with MKD-HIDS patient cells indicated that increased temperature, as caused by fever during an inflammatory episode, lowers the residual MK activity, which causes a temporary shortage of non-sterol isoprenoids that promotes the further development of inflammation. Because an increase of the residual MK activity is expected to make MKD-HIDS patients less sensitive to developing inflammatory episodes, we established a cell-based screen that can be used to identify compounds and/or therapeutic targets that promote this increase. Using a reporter HeLa cell line that stably expresses the most common MKD-HIDS variant, MK-V377I, C-terminally tagged with bioluminescent NanoLuc luciferase (nLuc), we screened the Prestwick Chemical Library (R), which includes 1280 FDA-approved compounds. Multiple compounds increased MK-V377I-nLuc bioluminescence, including steroids (i.e., glucocorticoids, estrogens, and progestogens), statins and antineoplastic drugs. The glucocorticoids increased MK-V377I-nLuc bioluminescence through glucocorticoid receptor signaling. Subsequent studies in MKD-HIDS patient cells showed that the potent glucocorticoid clobetasol propionate increases gene transcription of MVK and other genes regulated by the transcription factor sterol regulatory element-binding protein 2 (SREBP-2). Our results suggest that increasing the flux through the isoprenoid biosynthesis pathway by targeting the glucocorticoid receptor or SREBP-2 could be a potential therapeutic strategy in MKD-HIDS.
引用
收藏
页码:302 / 316
页数:15
相关论文
共 50 条
  • [31] Identification of FDA-approved drugs as novel allosteric inhibitors of human executioner caspases
    Deepak, R. N. V. Krishna
    Abdullah, Ahmad
    Talwar, Priti
    Fan, Hao
    Ravanan, Palaniyandi
    PROTEINS-STRUCTURE FUNCTION AND BIOINFORMATICS, 2018, 86 (11) : 1202 - 1210
  • [32] Molecular Recognition of FDA-Approved Small Molecule Protein Kinase Drugs in Protein Kinases
    Zhu, Yan
    Hu, Xiche
    MOLECULES, 2022, 27 (20):
  • [33] Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome
    Drenth, JPH
    Cuisset, L
    Grateau, G
    Vasseur, C
    van de Velde-Visser, SD
    de Jong, JGN
    Beckmann, JS
    van der Meer, JWM
    Delpech, M
    NATURE GENETICS, 1999, 22 (02) : 178 - 181
  • [34] Mutations in the gene encoding mevalonate kinase cause hyper-IgD and periodic fever syndrome
    Joost P.H. Drenth
    Laurence Cuisset
    Gilles Grateau
    Christian Vasseur
    Saskia D. van de Velde-Visser
    Jan G.N. de Jong
    Jacques S. Beckmann
    Jos W.M. van der Meer
    Marc Delpech & contributing members of the International Hyper-IgD Study Group
    Nature Genetics, 1999, 22 : 178 - 181
  • [35] Pharmacogenomic characterization of US FDA-approved cytotoxic drugs
    Peters, Eric J.
    Motsinger-Reif, Alison
    Havener, Tammy M.
    Everitt, Lorraine
    Hardison, Nicholas E.
    Watson, Venita G.
    Wagner, Michael
    Richards, Kristy L.
    Province, Mike A.
    McLeod, Howard L.
    PHARMACOGENOMICS, 2011, 12 (10) : 1407 - 1415
  • [36] Repurposing FDA-approved drugs as potential PARP inhibitors
    Eznarriaga, Maria
    Rahman, Taufiq
    BRITISH JOURNAL OF PHARMACOLOGY, 2020, 177 (11) : 2516 - 2516
  • [37] RNA as an off-target for FDA-approved drugs
    Fullenkamp, Christopher R.
    Schneekloth, John S.
    NATURE CHEMISTRY, 2023, 15 (10) : 1329 - 1331
  • [38] Pharmacogenetic Labeling of FDA-Approved Drugs A Regulatory Retrospective
    Drozda, Katarzyna
    Pacanowski, Michael A.
    Grimstein, Christian
    Zineh, Issam
    JACC-BASIC TO TRANSLATIONAL SCIENCE, 2018, 3 (04): : 545 - 549
  • [39] An analysis of FDA-approved drugs: natural products and their derivatives
    Patridge, Eric
    Gareiss, Peter
    Kinch, Michael S.
    Hoyer, Denton
    DRUG DISCOVERY TODAY, 2016, 21 (02) : 204 - 207
  • [40] Preapproval Promises to Voluntarily Withdraw FDA-Approved Drugs
    Lynch, Holly Fernandez
    Sachs, Rachel E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (24): : 2392 - 2393